• Fennec Pharmaceuticals disclosed new independent research on its cisplatin hearing-loss protective drug PEDMARK, with data slated for presentation at the 2026 ASCO annual meeting.
• The update highlights a Japanese pediatric and adolescent study that reported reduced hearing-loss outcomes versus expected rates, supporting broader use beyond the product’s current pediatric indication.
• Real-world analyses in young adults with solid tumors and adults with head and neck cancer indicated PEDMARK can be integrated into routine care when timed several hours after cisplatin, without apparent loss of anticancer effect.
• A new randomized Phase 1 trial in men with metastatic germ cell tumors opened to enrollment in January 2026, extending PEDMARK’s development into adult settings with high reported rates of cisplatin-related hearing damage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211801PRIMZONEFULLFEED9725105) on May 21, 2026, and is solely responsible for the information contained therein.